Fosamax (Alendronate) Bone Health and Density Impact: What Women Need to Know

What Alendronate Does to Your Bones

Alendronate works by suppressing osteoclast activity. Osteoclasts are the cells that break bone down. By slowing resorption without directly stopping bone formation, the drug shifts the remodeling balance toward net bone gain. The result is measurable increases in bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip.

In postmenopausal women, estrogen withdrawal accelerates osteoclast-driven bone loss at a rate of 1 to 3 percent per year in the early postmenopausal years. Alendronate does not replace estrogen, but it counteracts the osteoclast hyperactivity that estrogen normally restrains. Understanding that distinction matters when you are deciding between alendronate and hormone therapy.

How BMD Gains Are Measured and What They Mean

BMD is measured with dual-energy X-ray absorptiometry (DEXA). Your result is reported as a T-score. A T-score of -1.0 to -2.4 indicates osteopenia; -2.5 or below is osteoporosis by World Health Organization criteria.

Alendronate 10 mg daily (the older daily formulation equivalent to 70 mg weekly) produced lumbar spine BMD increases of approximately 8.8% over three years in the Fracture Intervention Trial (FIT). Femoral neck gains reached roughly 5.9% in the same cohort. These gains are statistically meaningful but do not fully capture fracture risk reduction, because bone quality, geometry, and microarchitecture also improve in ways that DEXA does not visualize.

The Fracture Intervention Trial: What FIT Actually Showed

The FIT trial is the landmark evidence base for alendronate. Published in JAMA in 1998, FIT enrolled 2,027 postmenopausal women aged 55 to 81 with low femoral neck BMD and at least one existing vertebral fracture. After three years of alendronate versus placebo, the alendronate group showed:

• A 47% reduction in new vertebral fractures (relative risk 0.53, 95% CI 0.41 to 0.68)
• A 51% reduction in hip fractures
• A 47% reduction in wrist fractures

The FIT also included a second arm of women without existing vertebral fracture. In that group, hip fracture reduction was 44% and clinical vertebral fracture reduction was 55% among women with T-scores at or below -2.5 at the femoral neck.

One clinically underappreciated finding from FIT: fracture benefit appeared within the first 12 to 18 months of treatment, well before maximum BMD gain was achieved. This tells you that structural bone changes begin early, even if your DEXA score does not yet look dramatically different.

How Female Physiology Shapes Alendronate's Effects

Reproductive Years and Premenopausal Osteoporosis

Premenopausal osteoporosis is uncommon and almost always has a secondary cause: long-term glucocorticoid use, anorexia, premature ovarian insufficiency, celiac disease, or cancer treatment. Evidence for alendronate in premenopausal women is extrapolated from postmenopausal data rather than from direct premenopausal trials. A 2003 ACOG Practice Bulletin acknowledges this data gap explicitly.

Alendronate accumulates in bone and can persist in the skeleton for years after stopping. For a premenopausal woman who may become pregnant, this long skeletal half-life is a serious concern and is a primary reason the drug is rarely the first choice in this group.

Perimenopause: The Window When Bone Loss Accelerates

Perimenopausal bone loss begins 1 to 2 years before the final menstrual period and accelerates sharply in the first 5 postmenopausal years. The Study of Women's Health Across the Nation (SWAN) found that lumbar spine BMD fell an average of 10.6% in the 6 years surrounding the final menstrual period, with the steepest decline in the 2 years after menopause.

During perimenopause, the threshold for starting alendronate depends on FRAX score (the WHO 10-year fracture probability tool) rather than DEXA T-score alone. The National Osteoporosis Foundation / American Bone Health guidelines recommend treatment when FRAX predicts a 10-year major osteoporotic fracture probability above 20% or a hip fracture probability above 3%, regardless of T-score.

Postmenopause: The Primary Treatment Window

Most prescriptions for alendronate go to postmenopausal women. The standard dose is 70 mg once weekly, taken with a full glass of plain water at least 30 minutes before the first food, drink, or other medication of the day. You must remain upright (sitting or standing) for at least 30 minutes after swallowing the tablet. Lying down risks esophageal erosion, the most common serious GI adverse effect.

BMD gains plateau after approximately 3 to 5 years of treatment. After that, many women continue to benefit from fracture protection even if DEXA numbers do not climb further, because of ongoing improvements in bone microarchitecture and mineralization.

Postmenopausal Women on Hormone Therapy: Can You Combine Them?

Yes, but you get modest additional BMD benefit over either agent alone, and the fracture data for combination use is limited. The 2022 Menopause Society position statement notes that hormone therapy (HT) itself reduces fracture risk and is a first-line option for women who are within 10 years of menopause onset and have no contraindications. For women who cannot take HT or who have T-scores below -2.5 despite HT, adding alendronate is a reasonable clinical decision.

Pregnancy and Lactation: This Drug Is Contraindicated in Pregnancy

Alendronate must not be used during pregnancy. This is not a relative caution. It is a contraindication.

Bisphosphonates cross the placenta and accumulate in fetal bone. Animal studies show fetal harm at doses equivalent to clinical human doses. Human data are limited to case reports and small series, and a 2008 case series published in Osteoporosis International documented cases of delayed bone development in infants born to mothers who took bisphosphonates inadvertently during pregnancy.

Because alendronate has an estimated skeletal retention half-life of more than 10 years, the drug may still be present in bone well after you stop taking it. For women who want to become pregnant, this persistence is a key counseling point. There is no established washout period that guarantees fetal safety. The FDA prescribing information for alendronate lists pregnancy as a contraindication.

Lactation

Whether alendronate transfers into human breast milk is unknown. Given the drug's mechanism and its accumulation in bone, prescribers and nursing women should treat this as an avoidance situation. No dose of alendronate during lactation has been established as safe.

Contraception Requirement

Any woman of reproductive age who is prescribed alendronate for premenopausal osteoporosis or glucocorticoid-induced osteoporosis must use reliable contraception throughout treatment. Because of skeletal retention, the contraception discussion should extend to the period after stopping the drug, with individualized counseling about timing any planned pregnancy.

Who This Is Right For, and Who Should Not Take It

Women Who Are Good Candidates

• Postmenopausal women with a DEXA T-score at or below -2.5 at the spine, hip, or femoral neck
• Postmenopausal women with a T-score between -1.0 and -2.5 and a FRAX 10-year hip fracture risk above 3%
• Women with glucocorticoid-induced osteoporosis (prednisone equivalent above 5 mg per day for 3 or more months)
• Women with a prior fragility fracture regardless of T-score
• Women with premature ovarian insufficiency and low BMD who cannot or will not take estrogen

Women Who Should Not Take Alendronate

• Pregnant women or women actively trying to conceive
• Women with esophageal abnormalities (stricture, achalasia, inability to stand or sit upright for 30 minutes)
• Women with estimated GFR below 35 mL per minute (dose accumulation risk; FDA label)
• Women with hypocalcemia (correct calcium deficiency before starting)
• Women with a documented allergy to alendronate or any component of the formulation

Dosing, Timing, and Practical Administration

The weekly 70 mg tablet replaced the daily 10 mg tablet as the standard of care after a randomized non-inferiority trial showed equivalent BMD gains and fracture risk reduction with better GI tolerability. Both doses achieve the same skeletal drug loading over time.

For osteopenia without prior fracture and a borderline FRAX score, the 35 mg weekly dose is approved to slow bone loss, though fracture reduction data for the 35 mg dose are less strong than for 70 mg.

Alendronate is also available as a 70 mg oral solution for women who cannot swallow tablets. An effervescent tablet formulation (Binosto) may reduce upper GI side effects.

Getting the Timing Right

Take alendronate first thing in the morning. Use plain water only, at least 240 mL (8 oz). Coffee, orange juice, mineral water, and calcium-containing drinks all reduce absorption by up to 60%. Remain upright for 30 minutes before eating or taking other medications, including calcium and vitamin D supplements.

Calcium and vitamin D are co-required. Without adequate calcium (1,000 to 1,200 mg per day from food and supplements combined) and vitamin D (800 to 1,000 IU per day), alendronate cannot produce its full BMD effect. ACOG recommends checking 25-hydroxyvitamin D levels before starting any bisphosphonate.

Side Effects Specific to Women

Upper GI Effects

Esophageal irritation, esophagitis, and esophageal ulceration are the most clinically significant side effects. Women with gastroesophageal reflux disease, hiatal hernia, or Barrett's esophagus are at higher baseline risk. The 30-minute upright rule and taking only plain water are the primary mitigation strategies.

Abdominal pain, nausea, and dyspepsia occur in 6 to 8% of women in clinical trials. These effects are dose-related and more common with the older daily regimen than with weekly dosing.

Musculoskeletal Pain

Severe bone, joint, or muscle pain has been reported with bisphosphonates, sometimes appearing months after the start of treatment. The FDA added a warning to the label in 2008 after receiving post-marketing reports. If you experience debilitating musculoskeletal pain that begins after starting alendronate, tell your prescriber.

Atypical Femoral Fractures

Atypical subtrochanteric or diaphyseal femoral fractures are a rare but serious concern with long-term bisphosphonate use. The absolute risk is low: approximately 3.2 to 50 per 100,000 patient-years, rising with treatment duration beyond 5 years. Warning symptoms include prodromal thigh or groin pain. Report this symptom to your clinician promptly.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) associated with oral bisphosphonate use for osteoporosis is very rare. The American Association of Oral and Maxillofacial Surgeons estimates risk at less than 1 in 10,000 to 1 in 100,000 patient-years for oral bisphosphonates at osteoporosis doses. Dental procedures are not contraindicated, but inform your dentist you are taking alendronate.

The Drug Holiday: When to Pause Alendronate

After 5 years of alendronate use in a woman at moderate fracture risk, many clinicians recommend a drug holiday of 1 to 2 years. The rationale is that bisphosphonate stored in bone continues to provide antiresorptive activity even without taking new doses, so the fracture benefit continues for a period after stopping.

The FLEX trial (JAMA, 2006) followed women who stopped alendronate after 5 years versus those who continued for 10 years. Women who continued for 10 years had fewer clinical vertebral fractures (2.4% vs. 5.3%) but no significant difference in hip fracture rates. This suggests that women at higher vertebral fracture risk benefit from continuing beyond 5 years.

A drug holiday is generally not appropriate for women with:

• A hip T-score below -2.5
• A prior hip or vertebral fracture
• An ongoing fall risk

After stopping, BMD begins to decline within 12 months in most women. Reassessment with DEXA at 2 to 3 years after the drug holiday begins is standard practice.

PCOS, Secondary Osteoporosis, and Other Conditions Alendronate Touches

PCOS

Women with PCOS often have lower BMD than age-matched controls, possibly related to lower estrogen bioavailability in some phenotypes and the metabolic effects of hyperinsulinemia on bone. A 2020 systematic review found that women with the hyperandrogenic PCOS phenotype had modestly lower femoral neck BMD. Alendronate is not a standard first-line treatment for PCOS-related bone concerns, but it is relevant if osteoporosis is detected on DEXA in a premenopausal woman with PCOS.

Glucocorticoid-Induced Osteoporosis

Women who take prednisone or equivalent for conditions like lupus, rheumatoid arthritis, or inflammatory bowel disease lose bone faster than natural menopause-related loss. ACR guidelines recommend starting alendronate in any woman taking glucocorticoids at above 7.5 mg prednisone equivalent per day for more than 3 months who is at medium or high fracture risk. This applies to premenopausal women with the appropriate FRAX score.

Premature Ovarian Insufficiency

Women with premature ovarian insufficiency (POI) diagnosed before age 40 lose bone at an accelerated rate due to prolonged estrogen deficiency. Estrogen therapy is the preferred first intervention. Alendronate is reserved for women with POI who have documented low BMD despite estrogen or who cannot use estrogen.

Monitoring: What to Expect After Starting Alendronate

Repeat DEXA at 1 to 2 years after starting alendronate to confirm a treatment response. A BMD increase of 3% or more at the lumbar spine is considered a positive response. If BMD continues to fall on alendronate, evaluate for secondary causes of bone loss (vitamin D deficiency, celiac disease, hyperparathyroidism, thyroid over-replacement) before switching agents.

Serum or urine bone turnover markers (C-telopeptide, N-telopeptide, procollagen type 1 N propeptide) can confirm biochemical response as early as 3 months after starting treatment. A reduction in C-telopeptide (CTX) of more than 50% from baseline suggests good adherence and drug effect.

Adherence is a major real-world problem. Only about 50% of women are still taking their bisphosphonate at 1 year in community pharmacy studies. The most common reasons for stopping are GI side effects and a sense that the drug is not doing anything visible. Monitoring bone markers and sharing DEXA comparisons with patients improves persistence.

Alendronate vs. Other Options: Where It Sits in the Treatment Algorithm

Thinking through the bisphosphonate and non-bisphosphonate choices helps clarify where alendronate belongs:

| Agent | Route | Frequency | Key advantage over alendronate | |---|---|---|---| | Alendronate (Fosamax) | Oral | Weekly | Lowest cost; generic available | | Risedronate (Actonel) | Oral | Weekly or monthly | Better tolerated with GI disease | | Zoledronic acid (Reclast) | IV infusion | Once yearly | Eliminates adherence problem | | Denosumab (Prolia) | SC injection | Every 6 months | Not contraindicated in low GFR; no jaw/AFF risk | | Raloxifene (Evista) | Oral | Daily | Also reduces breast cancer risk; useful in high-risk women | | Romosozumab (Evenity) | SC injection | Monthly x 12 | Anabolic plus antiresorptive; cardiovascular caution | | Teriparatide (Forteo) | SC injection | Daily | Anabolic; used in severe osteoporosis or failed bisphosphonate |

For most postmenopausal women starting osteoporosis treatment for the first time, alendronate is the standard first choice because it has the longest safety record, the most fracture data, and the lowest cost. Generic alendronate 70 mg weekly costs approximately $10 to $20 per month without insurance, compared to over $400 for branded IV or injectable alternatives.

For women who cannot tolerate oral alendronate due to GI problems, or who have severe osteoporosis (T-score below -3.0) or a very high fracture risk, an anabolic agent (teriparatide, romosozumab) or injectable antiresorptive (denosumab, zoledronic acid) may be more appropriate from the start.